Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association.

Authors

Manas Pustake, Stevenson Ongsyping, Jesus Gomez, Javier Corral

Published in

BMJ case reports. Volume 19. Issue 9. Sep 28, 2026. Epub Sep 28, 2026.

Abstract

Central retinal artery occlusion (CRAO) is a vision-threatening vascular emergency that often causes permanent monocular visual loss. We report a woman in her late seventies with metastatic hormone receptor-positive, HER2-negative breast cancer and multiple myeloma who developed sudden, painless right monocular vision loss while receiving long-term abemaciclib and lenalidomide. Funduscopic examination showed diffuse retinal whitening, attenuated retinal arterioles and a cherry-red spot, confirming CRAO. She presented approximately 20 hours after symptom onset, outside the window for hyperacute intervention and severe visual impairment persisted. Evaluation showed severe hypertension and extensive cardiovascular comorbidity but no high-grade carotid stenosis, large-vessel occlusion or definite cardiac embolic source. Abemaciclib and lenalidomide have each been associated predominantly with venous thromboembolism. Given the patient's multiple vascular and malignancy-related risk factors, a treatment-related contribution, including a possible synergistic interaction, cannot be excluded.

PMID:
42805625
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.